Palasi

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Retrieved on: 
Tuesday, April 25, 2023
CRS, Drug discovery, New Drug Application, Clinical trial, LYRA, Patient, Palasi, Sinusitis, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Lyra

The ENLIGHTEN program consists of two pivotal Phase 3 clinical trials, ENLIGHTEN I and ENLIGHTEN II, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS.

Key Points: 
  • The ENLIGHTEN program consists of two pivotal Phase 3 clinical trials, ENLIGHTEN I and ENLIGHTEN II, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS.
  • Enrollment in the ENLIGHTEN I clinical trial remains on track, with pivotal data anticipated in 1H 2024.
  • Lyra announced in November 2022 that it temporarily paused enrollment in ENLIGHTEN II due to a transition to in-house manufacturing to ensure consistent clinical supply of LYR-210.
  • The Company expects to complete enrollment in the ENLIGHTEN II trial in the second half of 2024.

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Retrieved on: 
Tuesday, July 5, 2022
LYRA, FDA, Patient, LinkedIn, Nose, Tissue, Legislation, Inflammation, Paranasal sinuses, ENT, COVID-19, Failure, Growth, Company, CRS, Terrorism, Lyra, Pharmacotherapy, Therapy, Palasi, Private Securities Litigation Reform Act, Lists of disasters, Ear, Nasdaq, Investor relations, SEC, Risk, Twitter, LYR, St. Regis New York, Conference, Pharmaceutical industry

(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference 2022 (the Conference).

Key Points: 
  • (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference 2022 (the Conference).
  • Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will take part in a fireside chat during the conference.
  • The Conference will be held at The St. Regis New York hotel from July 12-13, during which Lyra will also host one-on-one meetings with investors.
  • Lyra Therapeutics, Inc.is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 26, 2022
Company, Private Securities Litigation Reform Act, Terrorism, ENT, Nasdaq, Palasi, Patient, Inflammation, Therapy, Investor relations, COVID-19, Failure, Paranasal sinuses, Legislation, FDA, Conference, Lists of disasters, Pharmacotherapy, CRS, Lyra, Nose, LinkedIn, LYRA, Twitter, SEC, Growth, Ear, Risk, Tissue, Pharmaceutical industry, Communications satellite

ET (1:20 p.m. CT)

Key Points: 
  • ET (1:20 p.m. CT)
    The Jefferies Healthcare Conference (New York, NY) fireside chat on June 9, 2022, at 2:30 p.m.
  • ET
    Webcasts of the presentations will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com at the times and dates specified above.
  • Webcast replays will be available for at least 30 days following each event.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Paranasal sinuses, Private Securities Litigation Reform Act, Twitter, Nasdaq, Failure, CRS, ENT, Company, Legislation, Patient, Palasi, FDA, Risk, Annual report, Therapy, Investor relations, Tissue, Lists of disasters, Ear, Pharmacotherapy, LinkedIn, Inflammation, Bank, Conference, SEC, Nose, Lyra, Growth, LYRA, Pharmaceutical industry

ET (11:20 a.m. PT)

Key Points: 
  • ET (11:20 a.m. PT)
    The H.C. Wainwright Global Investment Conference (Miami, FL) corporate presentation on May 25, 2022, at 11:00 a.m.
  • ET
    Webcasts of the presentations will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com at the times and dates specified above.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.
  • Lyra's XTreo platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex.

Lyra Therapeutics Appoints Jim Tobin to Board of Directors

Retrieved on: 
Monday, March 7, 2022
Private Securities Litigation Reform Act, Failure, Lists of disasters, Patient, U.S. Navy Diving Manual, MBA, CRS, Palasi, Transmedics, Twitter, Doctor of Philosophy, LinkedIn, Board of directors, Baxter International, BOD, FDA, Growth, Therapy, A.B. Dick Company, LYRA, ENT, Board, Sinusitis, Ear, COVID-19, Inflammation, Harvard College, Harvard Business School, CEO, Lyra, Pharmacotherapy, COO, Risk, Nasdaq, Tissue, Boston Scientific, Legislation, Paranasal sinuses, Nose, Pharmaceutical industry, Biogen

WATERTOWN, Mass., March 7, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jim Tobin to its Board of Directors (BOD).

Key Points: 
  • WATERTOWN, Mass., March 7, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jim Tobin to its Board of Directors (BOD).
  • Tobin currently serves as Chairman of the Board at TransMedics, Inc. and Board Member ofeach of Globus Medical Inc., a publicly traded company, as well asImpulse Dynamics and Xenter Medical.
  • Mr. Tobin has served on the board of over 20 companies and was a Lieutenant in the U.S. Navy from 1968 to 1972.
  • Lyra Therapeutics, Inc.is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, November 11, 2021
Legislation, Private Securities Litigation Reform Act, Webcast, Therapy, Ear, Diagnosis, Tissue, LYRA, ENT, Palasi, Investor relations, Lyra, Failure, Growth, COVID-19, Nose, Pharmacotherapy, Lists of disasters, Risk, Sinusitis, Evercore, Twitter, Canaccord Genuity, Conference, Company, LinkedIn, SEC, Time, CRS, Nasdaq, Digital health, FDA, Pharmaceutical industry

ET

Key Points: 
  • ET
    The Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum corporate presentation on November 18, 2021 at 9:00 a.m.
  • ET
    The Evercore ISI 4th Annual HealthCONx Virtual Conference fireside chat on December 1, 2021 at 3:55 p.m.
  • ET
    Webcasts of the virtual presentations will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com at the times and dates specified above.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyras President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyras President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.
  • The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m.
  • A webcast of the virtual presentation will be available in the Investor Relations section of the Companys website at https://investors.lyratherapeutics.com .
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.